Replidyne, Inc. Says FDA Issues Warning Letter for Faropenem

Jan 28 (Reuters) - Replidyne Inc (RDYN.O: Quote, Profile, Research) said it received a warning letter from the U.S. Food and Drug Administration in regard to its antibiotic faropenem medoxomil 300 mg tablets twice per day dose.
MORE ON THIS TOPIC